Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
← catalyst calendarNCT04373564 · readout in 865 d
Sponsored by Guerbet (industry) · GBT.PA — their whole pipeline →. With Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor).
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
2,076estimated
Sites
51
Countries
Brazil, Canada, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-24 | actual | When the study began enrolling |
| Primary completion | 2028-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Motor Function
- Cognitive Function
- Contrast Media
Interventions
- Procedure: Motor Tests
- Procedure: Cognitive Tests
- Procedure: Unenhanced-MRI of the brain
- Procedure: Gadolinium Measurements
- Drug: Gadoxetate disodium — also filed as Eovist, Primovist, BAY86-4873
- Drug: Gadobenate dimeglumine — also filed as MultiHance
- Drug: Gadodiamide — also filed as Omniscan
- Drug: Gadoterate meglumine — also filed as Dotarem, Magnescope
- Drug: Gadobutrol — also filed as BAY86-4875, Gadavist, Gadovist
- Drug: Gadoteridol — also filed as ProHance
Primary outcomes
what the primary-completion date above is the date OFChange of motor function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group
measured At baseline, year 5
Change in cognitive function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group
measured At baseline, year 5
Permalink · GBT.PA's whole pipeline · Catalyst calendar · Every registered study · What changed